Is It Too Late to Buy Eli Lilly Stock? Here's What $1,000 Invested Today Could Be Worth in 10 Years.

Morgan Stanley estimates the obesity drug market could grow from ~$15B in 2024 to as much as ~$150B by 2035, positioning Eli Lilly to sustain long-run leadership. The article highlights Lilly’s pill-launch Foundayo (US launch April) and late-stage triple-agonist Retatrutide as new patent-protected growth catalysts. Using consensus 2026 EPS of $35.60 and an assumed ~15% annual EPS growth for 10 years, it projects EPS rising to ~$125.23 and an illustrative valuation at 25x by year 10 implying a ~$3,130/share price and ~158% potential upside (excluding dividends).

Analysis

Near-term, the market already knows obesity is a structurally large category; the bigger question is who captures the economics of access. LLY’s advantage is not just product breadth but the ability to convert demand into repeatable supply and then defend pricing with a faster launch cadence than peers. The risk is that investors extrapolate market-size growth into margin permanence, when the more likely intermediate outcome is a mix shift toward lower-ARPU oral therapy and heavier payer rebates.

Over the next 1-3 months, the important catalysts are not commentary pieces but hard evidence: prescription share trends, formulary coverage, and whether oral uptake is incremental or cannibalistic. If oral adoption broadens the treated population without materially lowering realized net price per patient, LLY can keep compounding; if access comes with aggressive discounts, the stock can still go up while the multiple compresses. NVO is the cleanest public loser if LLY continues to out-execute on sequence and capacity, but the real second-order loser may be broad biotech sentiment, because this is one of the few growth stories where cash flows are already visible.

The contrarian miss is that consensus may be underestimating how quickly the market turns into a managed-care negotiation rather than a pure growth story. A decade-long TAM expansion can coexist with flat-to-lower forward P/E if payers, competitors, and compounding-enforcement dynamics force a race to the bottom on net pricing. Falsifiers: slowing obesity franchise growth below the high-20s to low-30s range, a safety/regulatory setback on next-gen assets, or any sign that NVO re-accelerates share in oral prescriptions.

Key Decisions for Investors

• Long LLY on 6-12 month horizon, but prefer entry on pullbacks after catalyst-driven volatility; thesis breaks if obesity gross margin compresses materially or formulary wins come with outsized rebates.
• Relative value: long LLY / short NVO for 3-6 months if share data confirm LLY’s launch execution advantage; cover if NVO’s oral franchise gains prescription share or if LLY hits any safety/regulatory snag.
• If already long LLY, consider selling upside into any sharp rerating rather than paying full multiple for the story; the risk/reward is better on dips than chasing momentum above a premium valuation.
• Set an alert for monthly prescription and coverage data; if growth decelerates or net price realization weakens, expect multiple compression before earnings revisions catch down.